Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
基于 CRISPR 的非病毒 PD1 基因座特异性整合的抗 CD19 CAR-T 细胞在复发或难治性非霍奇金淋巴瘤患者中的安全性和有效性:一项首次在人体进行的 I 期研究
期刊:EClinicalMedicine
影响因子:9.6
doi:10.1016/j.eclinm.2023.102010
Yongxian Hu, Cheng Zu, Mingming Zhang, Guoqing Wei, Wei Li, Shan Fu, Ruimin Hong, Linghui Zhou, Wenjun Wu, Jiazhen Cui, Dongrui Wang, Bing Du, Mingyao Liu, Jiqin Zhang, He Huang